Who are CG53135-05, velafermin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kepivance (Palifermin), Palifermin before only.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cg53135-05-velafermin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CG53135-05, velafermin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CG53135-05, velafermin (CG53135-05, velafermin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibroblast growth factor. Area: Wound healing.

phase 2 Fibroblast growth factor FGF receptors Wound healing Small molecule Live · refreshed every 30 min

Target snapshot

CG53135-05, velafermin (CG53135-05, velafermin) — CuraGen Corporation. Velafermin is a recombinant human fibroblast growth factor 2 (FGF-2) that stimulates angiogenesis and wound healing.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CG53135-05, velafermin TARGET	CG53135-05, velafermin	CuraGen Corporation	phase 2	Fibroblast growth factor	FGF receptors
Kepivance (Palifermin)	Kepivance (Palifermin)	Swedish Orphan Biovitrum	marketed	Fibroblast growth factor (FGF) receptor agonist	FGFR2 (Fibroblast Growth Factor Receptor 2)
Palifermin before only	Palifermin before only	Swedish Orphan Biovitrum	phase 3	Fibroblast growth factor (FGF) analog	FGFR2 (Fibroblast Growth Factor Receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibroblast growth factor class)

CuraGen Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CG53135-05, velafermin — Competitive Intelligence Brief. https://druglandscape.com/ci/cg53135-05-velafermin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab